Seer (SEER)
Provides the Proteograph platform for deep, unbiased proteomics research.
$1.86
After-hours close−0.01 (−0.53%)
At close$1.87(+0.54%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Cost of revenue | 4 | 2 | 3 | 3 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 2 |
| Gross profit | 1 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 1 | 2 |
| 27 | 24 | 25 | 27 | 26 | 24 | 23 | 23 | 21 | 19 | 18 | 18 | |
| Research & development | 12 | 11 | 11 | 11 | 13 | 11 | 11 | 12 | 11 | 10 | 9 | 8 |
| 15 | 13 | 14 | 16 | 13 | 13 | 11 | 11 | 11 | 10 | 9 | 10 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −26 | −22 | −25 | −27 | −24 | −24 | −21 | −21 | −19 | −17 | −17 | −17 |
| 5 | 4 | 5 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | |
| Interest income | 5 | 5 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
| Other non-operating income | −5 | −4 | −5 | −4 | −3 | −2 | 0 | 0 | 0 | 0 | 0 | −2 |
| Income before tax | −21 | −18 | −21 | −23 | −21 | −22 | −20 | −19 | −18 | −16 | −17 | −17 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −21 | −18 | −21 | −23 | −21 | −22 | −20 | −19 | −18 | −16 | −17 | −17 |
| Net income | −21 | −18 | −21 | −23 | −21 | −22 | −20 | −19 | −18 | −16 | −17 | −17 |
| EPS, basic | −$0.33 | −$0.28 | −$0.32 | −$0.35 | −$0.35 | −$0.35 | −$0.34 | −$0.33 | −$0.32 | −$0.29 | −$0.30 | −$0.31 |
| EPS, diluted | −$0.33 | −$0.28 | −$0.32 | −$0.35 | −$0.35 | −$0.35 | −$0.34 | −$0.33 | −$0.32 | −$0.29 | −$0.30 | −$0.31 |
| Weighted average shares, basic | 64 | 64 | 65 | 65 | 61 | 61 | 59 | 58 | 56 | 57 | 56 | 55 |
| Weighted average shares, diluted | 64 | 64 | 65 | 65 | 61 | 61 | 59 | 58 | 56 | 57 | 56 | 55 |
| EBITDA | −20 | −16 | −19 | −21 | −20 | −20 | −19 | −19 | −18 | −16 | −16 | −15 |
| Depreciation & amortization | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 |
| EBIT | −21 | −18 | −21 | −23 | −21 | −22 | −21 | −21 | −19 | −17 | −17 | −15 |
